Carrascosa JM, Vanaclocha F, Caloto T, Echave M, Oyagüez I, Tencer T
Cost-utility analysis of apremilast for the treatment of moderate to severe psoriasis in Spain
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Echave M, Ojanguren ME, Elías I, De Andrés-Nogales F, Oyagüez I, Casado MÁ, Crespo C
Cost-effectiveness of tiotropium in the treatment of patients with asthma
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Echave M, Oyagüez I, Lamas MJ, Rubio M, Subirá R
Aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer: cost-effectiveness based on VELOUR Best Efficacy Subgroup post-hoc analysis
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Rodríguez-González Moro JM, Menendez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F
Cost-effectiveness of a 13-valent conjugate pneumococcal vaccination program in COPD patients aged 50+ years in Spain
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Ortega-Joaquin N, Elías I, de la Cueva P, Del Pozo LJ, Boada A, Moreno D, Aguilar M, Mosquera E, Mirada A, Gibbons C, Oyagüez I
Cost-effectiveness of ingenol mebutate versus imiquimod 5% for actinic keratosis treatment in Spain
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Elias I, Ortega-Joaquin N, Aguilar M, Moreno D, Boada A, Del Pozo LJ, De la Cueva P, Mirada A, Mosquera E, Gibbons C, Oyagüez I
Cost-utility analysis of ingenol mebutate versus diclofenac 3% for actinic keratosis treatment in Spain
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Gros B, Galan A, Gonzalez-Parra E, Herrero JA, Echave M, Vegter S, Tolley K, Oyagüez I
Cost effectiveness of Lanthanum Carbonate in chronic kidney disease patients in Spain before and during dialysis
Health Econ Rev. 2015;5:14 doi:10.1186/s13561-015-0049-3
González-Parra E, Gros B, Galán A, Herrero JA, Oyagüez I, Keith M, Casado MA
Análisis coste-efectividad de carbonato de lantano frente a hidrocloruro de sevelámero en el tratamiento de la hiperfosfatemia en pacientes con enfermedad renal crónica en España
Pharmacoeconomics Span Res Art. 2015;12(1):11-22
Oyagüez I, Echave M, Gómez-Barrera M, Ramírez-Boix P, Martinez J